Guardant Health (NASDAQ:GH) has received approval from the U.S. FDA for its Guardant360 CDx, which serves as a companion diagnostic tool. The Guardant360 CDx is specifically approved for use alongside Inluriyo, developed by Eli Lilly (LLY), in treating adults ...

Guardant Health (NasdaqGS:GH) 2025 Investor Day September 24, 2025 09:00 AM ET Company ParticipantsCraig Eagle - Chief Medical OfficerJenn Higgins - SVP of Global Public AffairsStephen Murphy - SVP of Marketing for ScreeningNone - Video NarratorChris Freeman - Chief Commercial Officer for OncologyJamie Boyle - SVP of Business DevelopmentMike Bell - CFOAmirAli Talasaz - Co-CEO and Co-FounderHelmy Eltoukhy - Co-CEO and Co-FounderDarya Chudova - CTOZarak Khurshid - VP of Investor RelationsDan Aries - Managing ...